Eagle Asset Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Eagle Asset Management’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-337,609	Closed	-$9.06M	–	613
2022 Q1	$9.06M	Sell	337,609 -29,228	-8%	-$982K	0.05%	287
2021 Q4	$17.8M	Sell	366,837 -30,665	-8%	-$1.37M	0.08%	226
2021 Q3	$26.4M	Sell	397,502 -32,798	-8%	-$2.34M	0.12%	195
2021 Q2	$33.6M	Buy	430,300 +4,427	+1%	+$327K	0.14%	188
2021 Q1	$38.6M	Buy	425,873 +43,462	+11%	+$5.17M	0.17%	184
2020 Q4	$46.6M	Sell	382,411 -57,412	-13%	-$6.29M	0.26%	141
2020 Q3	$38.9M	Sell	439,823 -2,891	-0.7%	-$201K	0.2%	170
2020 Q2	$28.3M	Buy	442,714 +329,307	+290%	+$19M	0.16%	187
2020 Q1	$5.06M	Buy	+113,407	New	+$6.02M	0.03%	361

Other funds holding TPTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Eagle Asset Management's TPTX Position: Q2 2022 in Review

Eagle Asset Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2022, closing a stake of 337,609 shares — an estimated $9.06M sold.

Eagle Asset Management first reported a position in TPTX in Q1 2020 and held it in 9 quarters. The position peaked at $46.6M in Q4 2020. 208 funds tracked by Wall St. Rank hold TPTX as of Q2 2022.

Eagle Asset Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Eagle Asset Management sold 337,609 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $9.06M.
Eagle Asset Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q1 2020 and held it in 9 quarters.
Eagle Asset Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $46.6M in Q4 2020.
208 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Eagle Asset Management's 13F filing for Q2 2022, filed 10 Aug 2022.